Moleculin Biotech (MBRX) PT Set at $8.00 by Roth Capital
The firm currently has a "buy" rating on the stock. Roth Capital's price target suggests a potential upside of 488.24% from the stock's previous close.
from Biotech News
The firm currently has a "buy" rating on the stock. Roth Capital's price target suggests a potential upside of 488.24% from the stock's previous close.
The most important thing is to improve and not stop. Even if you have taken some course, this does not mean that you are now a guru. You need to constantly practice, learn something new.
0 Comments